Johnson Chemical Pharmaceutical Works Co Ltd (4747) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Johnson Chemical Pharmaceutical Works Co Ltd TWD 12.67, price TWD 23.80, upside -46.8%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Johnson Chemical Pharmaceutical Works Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 12.37 TWD – 70.17 TWD · fair‑value band 9.71 TWD – 14.05 TWD · the 23.80 TWD price screens above the 12.67 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Johnson Chemical Pharmaceutical Works Co in your weekly email
Every Wednesday you see whether Johnson Chemical Pharmaceutical Works Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms.
Show more
Johnson Chemical Pharmaceutical Works Co., Ltd. manufactures, imports, and sells pharmaceutical ingredients, materials and products in Taiwan. The company manufactures drugs in a variety of forms, such as solid dosage form, capsule, tablet, and powder and granule, as well as nasal spray forms. It offers its products in various therapeutic areas, including central nervous system, respiratory, cardiovascular, gastrointestinal, endocrine system, vitamins, anti-inflammatory, cough and cold, pain reliever, etc. The company was founded in 1959 and is based in New Taipei City, Taiwan.
Stock analysis
Johnson Chemical Pharmaceutical Works Co Ltd (4747) currently trades at 23.80 TWD, while our model-based Fair Value estimate is 12.67 TWD, implying the stock looks roughly 87.8% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 17.22 TWD per share, and 2 of the 25 models we run sit above the 23.80 TWD price.
Bear case: the Dividend Discount group reads lowest at 8.47 TWD, and 23 of the 25 models stay below the price. Evidence for this calculation is low.
Scenario range: 9.71 TWD (bear) to 14.05 TWD (bull), the price of 23.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Johnson Chemical Pharmaceutical Works Co Ltd reported revenue of 570M TWD in FY2025 versus 411M TWD in FY2021, a compound +8.5%/yr. Reported net income was 53.5M TWD in FY2025, compounding +2.2%/yr from FY2021.
Key figures
Market cap 4.4B TWD (≈ $140M) · P/E ratio 41.0 · P/S ratio 3.85 · EPS (TTM) 1.19 TWD · Dividend yield 4.4% · Net margin 9.4% · Return on equity 5.6% · Return on assets (EBIT) 5.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 66% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −47%, 4747 screens richer than that median.
Fair Value models
Bear 9.71 TWDFair Value 12.67 TWDBull 14.05 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.1036 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−6.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−4.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.5%
Dividend (yield on the price)4.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 13%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +28.9% a year for the price.
Compare Johnson Chemical Pharmaceutical Works Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 623 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−46.8% · Below median
Profitability
Return on equity (TTM)5.6% · Below median
Return on assets1.6% · Below median
Net margin (TTM)17.3% · Top 25%
Operating margin (TTM)10.0% · Above median
Growth and dividend
Revenue growth−0.1% · Below median
Dividend yield (TTM)4.4% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)41.0× · Pricier than median
P/B2.60× · Pricier than median
P/S (TTM)7.79× · Priciest 25%
P/FCF18.3× · Priciest 25%
EV/EBITDA40.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 13
FUTURE (revenue growth)0· sector 18
PAST (return on equity)22· sector 26
HEALTH (low debt)100· sector 96
DIVIDEND (yield)88· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Johnson Chemical Pharmaceutical Works Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4747
Frequently asked questions
Is Johnson Chemical Pharmaceutical Works Co Ltd (4747) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 12.67 TWD versus a price of 23.80 TWD, about −47% upside (overvalued).
What is the fair value of 4747?
Our model-based fair value for Johnson Chemical Pharmaceutical Works Co Ltd is 12.67 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 23.80 TWD.
What is the quality score of 4747?
Johnson Chemical Pharmaceutical Works Co Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Our model-based price target is the fair value of 12.67 TWD (as of Sep 24, 2026) from 25 valuation models. Cautious scenario 9.71 TWD, optimistic scenario 14.05 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Johnson Chemical Pharmaceutical Works Co Ltd stock forecast for 2026?
Our models put fair value at 12.67 TWD, about −47% upside versus a price of 23.80 TWD (overvalued). Cautious scenario 9.71 TWD, optimistic scenario 14.05 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Johnson Chemical Pharmaceutical Works Co Ltd reported trailing-twelve-month revenue of about 570M TWD (latest available figure, as of Sep 24, 2026).
Does Johnson Chemical Pharmaceutical Works Co Ltd pay a dividend?
Johnson Chemical Pharmaceutical Works Co Ltd currently shows a dividend yield of about 4.41% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
For today's price to be fair in a discounted-cash-flow model, Johnson Chemical Pharmaceutical Works Co Ltd would have to grow free cash flow by +31.0 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 4747 use?
Our models discount Johnson Chemical Pharmaceutical Works Co Ltd at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Johnson Chemical Pharmaceutical Works Co Ltd that is +31.0 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Johnson Chemical Pharmaceutical Works Co Ltd (4747) delivered so far?
Over the past 5 years revenue at Johnson Chemical Pharmaceutical Works Co Ltd grew +6.1 % a year. The price currently implies +31.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Johnson Chemical Pharmaceutical Works Co Ltd (4747) growing?
The median revenue growth in the sector is +4.1 % a year. That is the yardstick for the growth priced into Johnson Chemical Pharmaceutical Works Co Ltd (+31.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The free-cash-flow yield on the price is 0.71 %: that much free cash flow Johnson Chemical Pharmaceutical Works Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Johnson Chemical Pharmaceutical Works Co Ltd it is 12.67 TWD per share (as of Sep 24, 2026), against a price of 23.80 TWD. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Johnson Chemical Pharmaceutical Works Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4747 trades above its calculated fair value: price 23.80 TWD, fair value 12.67 TWD, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4747?
No. The price is what the market pays today (23.80 TWD); the fair value is what the company's own numbers justify (12.67 TWD). For Johnson Chemical Pharmaceutical Works Co Ltd the two are 11.13 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Johnson Chemical Pharmaceutical Works Co Ltd worth?
The market values Johnson Chemical Pharmaceutical Works Co Ltd at about 4.4B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 23.80 TWD; our models calculate a fair value of 12.67 TWD per share.
What do the bullish and bearish scenarios say about 4747?
Our models span a range for Johnson Chemical Pharmaceutical Works Co Ltd: cautious scenario 9.71 TWD, base 12.67 TWD, optimistic 14.05 TWD per share (as of Sep 24, 2026, price 23.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4747?
Johnson Chemical Pharmaceutical Works Co Ltd trades at a price-to-earnings ratio of 41.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 12.67 TWD is built from several models across several years. Other multiples: P/B 2.6, P/S 7.8, EV/EBITDA 40.6.
How solid is the balance sheet of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Balance-sheet figures for Johnson Chemical Pharmaceutical Works Co Ltd (as of Sep 24, 2026): return on equity 5.6%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 4747 from its 52-week high?
Johnson Chemical Pharmaceutical Works Co Ltd trades at 23.80 TWD, about 66% below its 52-week high of 70.17 TWD and 1% above the low of 23.60 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 12.67 TWD is for.
Which stocks are comparable to Johnson Chemical Pharmaceutical Works Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Johnson Chemical Pharmaceutical Works Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 23.80 TWD, calculated fair value 12.67 TWD (−47%), Quality Score 40/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4747 calculated?
We run Johnson Chemical Pharmaceutical Works Co Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12.67 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Johnson Chemical Pharmaceutical Works Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The closing price on Sep 24, 2026 was 23.80 TWD. Our model-based fair value is 12.67 TWD, about −47% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Johnson Chemical Pharmaceutical Works Co Ltd right now?
The price sits above even our optimistic bull case (14.05 TWD). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Johnson Chemical Pharmaceutical Works Co Ltd
How large is the market capitalisation of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The market capitalisation of Johnson Chemical Pharmaceutical Works Co Ltd is 4.4B TWD (≈ $140M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The price-to-sales ratio of Johnson Chemical Pharmaceutical Works Co Ltd is 3.85 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Earnings per share at Johnson Chemical Pharmaceutical Works Co Ltd are 1.19 TWD (price ÷ EPS = P/E 41.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The dividend yield of Johnson Chemical Pharmaceutical Works Co Ltd is 4.4% (payout 88.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The net margin of Johnson Chemical Pharmaceutical Works Co Ltd is 9.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The return on equity (ROE) of Johnson Chemical Pharmaceutical Works Co Ltd is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
On an EBIT basis the return on assets of Johnson Chemical Pharmaceutical Works Co Ltd is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
The operating margin of Johnson Chemical Pharmaceutical Works Co Ltd is 10.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Revenue at Johnson Chemical Pharmaceutical Works Co Ltd is growing −0.1% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Johnson Chemical Pharmaceutical Works Co Ltd (4747)?
Earnings per share at Johnson Chemical Pharmaceutical Works Co Ltd are growing +201% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Johnson Chemical Pharmaceutical Works Co Ltd in the live analysis
One click puts Johnson Chemical Pharmaceutical Works Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
